Compare Amgen, Inc. (AMGN) vs Capri Holdings Ltd (CPRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Capri Holdings Ltd — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Capri Holdings Ltd trades at $18.04 (market cap $2.07B). The key difference: Amgen, Inc. is far larger — about 94.7× Capri Holdings Ltd's market cap, and Amgen, Inc. pays a 2.77% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals.
| AMGN | CPRI | |
|---|---|---|
Market Cap | $196.12B | $2.07B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $27.66 |
52-Week Low | $271.18 | $16.79 |
Enterprise Value | $241.41B | $3.36B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CPRI trades at $18.04, down 0.22% with bearish technical signals. The company reported mixed Q4 2026 results with an EPS beat but revenue challenges, while showing a net loss of $1.18 billion in 2025. Analyst consensus is divided with a $23.33 price target, and recent news highlights a post-Versace turnaround focus on Michael Kors and Jimmy Choo brands.
The outlook hinges on successful execution of brand revamps and cost controls. Key risks include luxury demand volatility and high debt, but current valuation metrics like P/S of 0.62 may offer value if the turnaround gains traction. Institutional sentiment is cautiously optimistic with 44% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →
